Updates are available Correction dated 2022-08-04

Article History

Received: 4 March 2022

Accepted: 11 May 2022

First Online: 17 June 2022

Change Date: 4 August 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00392-022-02066-3

Declarations

:

: Andreas Metzner has received speakers honoraria from Medtronic, Biosense Webster, Boston Scientific and Cardiofocus. Daniel Steven has received speakers honoraria from Abbott, Boston Scientific and Biosense Webster and he received research grants from Medtronic, Abbott and Biosense Webster. Philipp Sommer is Member of the Advisory Board for Abbott, Biosense Webster, Boston Scientific and Medtronic. PK was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961; PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation. Paulus Kirchhof receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Andreas Rillig received consultant fees from Medtronic, KODEX-EPD, Biosense Webster and travel grants and lecture fees from Medtronic, Cardiofocus, Biosense Webster, Abbott, Boehringer Ingelheim, Philips KODEX-EPD, Ablamap, Bayer and Novartis.